MEDIKA, dioničko društvo za trgovinu lijekovima i sanitetskim materijalom financials
MEDIKA, dioničko društvo za trgovinu lijekovima i sanitetskim materijalom
Country: HR Reporting currency: HRK Latest annual report: 2022-12-31
LEI:
74780000O0R8ZVGJJO27 Financial statements
(HRK, as reported — unscaled; 96 line items across 2 annual periods)
| Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Revenue | HRK 4.73B | HRK 4.13B |
| Employee benefits expense | HRK 152.7M | HRK 142.6M |
| Depreciation & amortisation | HRK 30.4M | HRK 29.2M |
| Operating profit (EBIT) | HRK 135.2M | HRK 111.9M |
| Net finance income / (cost) | HRK 17.0M | HRK 6.1M |
| Finance costs | HRK 2.9M | HRK 4.5M |
| Profit before tax | HRK 155.5M | HRK 120.9M |
| Income tax expense | HRK 38.8M | HRK 21.3M |
| Profit for the year | HRK 116.7M | HRK 99.5M |
| Total comprehensive income | HRK 116.7M | HRK 99.5M |
| Per share | ||
| Basic EPS | HRK 4032.05 | HRK 3524.69 |
| Free cash flow / share | HRK 1908.27 | HRK 9551.15 |
| Cash flow statement | ||
| Cash generated from operations | HRK 101.4M | HRK 358.8M |
| Net cash from operating activities | HRK 68.8M | HRK 333.4M |
| Net cash from investing activities | HRK 7.0M | -HRK 58.6M |
| Purchase of PP&E (capex) | HRK 13.5M | HRK 63.7M |
| Purchase of intangibles | HRK 3.4M | HRK 7.1M |
| Net cash from financing activities | HRK 247.3M | -HRK 268.1M |
| Dividends paid | HRK 40.5M | HRK 38.2M |
| Proceeds from borrowings | HRK 520.0M | HRK 487.0M |
| Repayments of borrowings | HRK 216.2M | HRK 728.8M |
| Lease liability payments | HRK 16.0M | HRK 15.2M |
| Balance sheet | ||
| Total assets | HRK 3.06B | HRK 2.33B |
| Non-current assets | HRK 563.2M | HRK 546.8M |
| Property, plant & equipment | HRK 233.4M | HRK 232.6M |
| Right-of-use assets | HRK 54.8M | HRK 49.1M |
| Intangible assets & goodwill | HRK 243.2M | HRK 232.9M |
| Current assets | HRK 2.49B | HRK 1.78B |
| Inventories | HRK 467.1M | HRK 356.5M |
| Trade & other receivables | HRK 1.62B | HRK 1.34B |
| Cash & equivalents | HRK 408.2M | HRK 85.1M |
| Total equity | HRK 718.5M | HRK 638.9M |
| Non-current liabilities | HRK 114.1M | HRK 121.2M |
| Long-term borrowings | HRK 17.2M | HRK 34.4M |
| Lease liabilities (non-current) | HRK 42.2M | HRK 37.6M |
| Current liabilities | HRK 2.23B | HRK 1.57B |
| Lease liabilities (current) | HRK 15.7M | HRK 13.6M |
| Trade & other payables | HRK 1.85B | HRK 1.53B |
| Deferred tax liabilities | HRK 21.2M | HRK 19.4M |
| Derived metrics | ||
| Free cash flow | HRK 55.3M | HRK 269.6M |
| Operating margin | 2.9% | 2.7% |
| Net margin | 2.5% | 2.4% |
| Return on equity | 16.2% | 15.6% |
| Cash conversion ratio | 0.59× | 3.35× |
| Capex coverage | 5.08× | 5.23× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -HRK 116.2M | HRK 9.8M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -HRK 279.9M | HRK 313.5M |
| Adjustments For Depreciation and Amortisation Expense | HRK 30.4M | HRK 29.2M |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | HRK 1.1M | HRK 216.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | HRK 821.0K | HRK 0 |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Inventories | HRK 6.1M | HRK 8.4M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Trade and Other Receivables | HRK 715.0K | -HRK 776.0K |
| Adjustments For Income Tax Expense | HRK 38.8M | HRK 21.3M |
| Adjustments For Increase Decrease In Trade and Other Payables | HRK 327.8M | -HRK 118.6M |
| Adjustments For Interest Expense | HRK 2.8M | HRK 4.5M |
| Adjustments For Interest Income | HRK 19.9M | HRK 10.5M |
| Adjustments For Provisions | HRK 16.0K | HRK 776.0K |
| Adjustments For Sharebased Payments | HRK 3.4M | HRK 5.0M |
| Adjustments For Undistributed Profits of Associates | HRK 3.3M | HRK 2.8M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -HRK 207.0K | HRK 1.6M |
| Advertising Expense | HRK 9.8M | HRK 8.3M |
| Cash Advances and Loans Made To Other Parties Classified As Investing Activities | HRK 2.5M | HRK 0 |
| Cash Flows From Used In Decrease Increase In Shortterm Deposits and Investments | -HRK 57.0K | -HRK 46.0K |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | HRK 12.2M | HRK 10.6M |
| Cash Receipts From Repayment of Advances and Loans Made To Other Parties Classified As Investing Activities | HRK 8.4M | HRK 7.4M |
| Cost of Merchandise Sold | HRK 4.35B | HRK 3.79B |
| Current Borrowings and Current Portion of Noncurrent Borrowings | HRK 338.4M | HRK 17.2M |
| Current Provisions | HRK 532.0K | HRK 342.0K |
| Current Tax Liabilities Current | HRK 20.5M | HRK 11.5M |
| Deferred Tax Assets | HRK 970.0K | HRK 999.0K |
| Dividends Received Classified As Investing Activities | HRK 3.1M | HRK 1.2M |
| Equity and Liabilities | HRK 3.06B | HRK 2.33B |
| Finance Income | HRK 19.9M | HRK 10.6M |
| Income Taxes Paid Refund Classified As Operating Activities | HRK 30.0M | HRK 20.6M |
| Increase Decrease In Cash and Cash Equivalents | HRK 323.1M | HRK 6.6M |
| Increase Decrease Through Sharebased Payment Transactions | HRK 3.4M | HRK 5.0M |
| Increase Decrease Through Transactions With Owners | -HRK 37.1M | -HRK 6.1M |
| Increase Decrease Through Treasury Share Transactions | — | HRK 27.0M |
| Interest Paid Classified As Operating Activities | HRK 2.6M | HRK 4.8M |
| Interest Received Classified As Investing Activities | HRK 19.9M | HRK 10.5M |
| Investments In Associates Accounted For Using Equity Method | HRK 26.0M | HRK 25.9M |
| Issued Capital | HRK 191.4M | HRK 191.4M |
| Noncurrent Payables | HRK 32.3M | HRK 28.4M |
| Noncurrent Provisions | HRK 1.2M | HRK 1.4M |
| Noncurrent Receivables | HRK 4.9M | HRK 5.4M |
| Other Adjustments For Noncash Items | -HRK 22.0K | HRK 13.0K |
| Other Adjustments To Reconcile Profit Loss | HRK 75.0K | HRK 0 |
| Other Comprehensive Income | HRK 0 | HRK 0 |
| Other Expense By Nature | HRK 60.9M | HRK 51.9M |
| Other Gains Losses | HRK 4.8M | HRK 1.5M |
| Other Reserves | HRK 67.4M | HRK 67.4M |
| Proceeds From Disposals of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | HRK 7.2M | HRK 2.7M |
| Proceeds From Government Grants Classified As Investing Activities | HRK 0 | HRK 1.0M |
| Proceeds From Sale Or Issue of Treasury Shares | HRK 0 | HRK 27.0M |
| Retained Earnings | HRK 459.7M | HRK 380.1M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | HRK 3.3M | HRK 2.8M |
Methodology
Every line item above is a fact tagged in MEDIKA, dioničko društvo za trgovinu lijekovima i sanitetskim materijalom's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (HRK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.